rizatriptan has been researched along with ly 293558 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bell, MG; Bleakman, D; Bleisch, TJ; CastaƱo, AM; Clemens-Smith, A; del Prado, M; Dieckman, DK; Dominguez, E; Escribano, A; Filla, SA; Ho, KH; Hudziak, KJ; Johnson, KW; Katofiasc, MA; Martinez-Perez, JA; Mateo, A; Mathes, BM; Mattiuz, EL; Ogden, AM; Ornstein, PL; Phebus, LA; Stack, DR; Stratford, RE; Winter, MA | 1 |
1 other study(ies) available for rizatriptan and ly 293558
Article | Year |
---|---|
Ethyl (3S,4aR,6S,8aR)-6-(4-ethoxycar- bonylimidazol-1-ylmethyl)decahydroiso-quinoline-3-carboxylic ester: a prodrug of a GluR5 kainate receptor antagonist active in two animal models of acute migraine.
Topics: Acute Disease; Administration, Oral; Animals; Biological Availability; Calcium; Carboxylic Acids; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Esters; Excitatory Amino Acid Antagonists; Humans; Isoquinolines; Migraine Disorders; Prodrugs; Radioligand Assay; Rats; Rats, Wistar; Receptors, Kainic Acid | 2002 |